



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/31, C12N 15/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/63243</b> <b>(43) International Publication Date:</b> 26 October 2000 (26.10.00)
<b>(21) International Application Number:</b> PCT/SE00/00732 <b>(22) International Filing Date:</b> 17 April 2000 (17.04.00) <b>(30) Priority Data:</b> 9901379-9                      19 April 1999 (19.04.99)                      SE <b>(71) Applicant (for all designated States except US):</b> PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LJUNGQVIST, Charlotta [SE/SE]; Dalkarlsgränd 3, S-168 58 Bromma (SE). NORD, Karin [SE/SE]; Tideliussgatan 32, S-118 69 Stockholm (SE). NYGREN, Per-Åke [SE/SE]; Pilotgatan 22, S-128 32 Skarpnäck (SE). UHLÉN, Mathias [SE/SE]; Måsvägen 8B, S-183 57 Täby (SE). <b>(74) Agents:</b> HÖGLUND, Lars et al.; Pharmacia & Upjohn AB, S-112 87 Stockholm (SE).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> DERIVATIVES OF THE B OR Z DOMAIN FROM STAPHYLOCOCCAL PROTEIN A (SPA) INTERACTING WITH AT LEAST ONE DOMAIN OF HUMAN FACTOR VIII  <b>(57) Abstract</b>  The present invention relates to modified polypeptides which are derivatives of the B domain or Z domain from staphylococcal protein A (SPA), wherein between 1 and 20 amino acid residues of the said B or Z domain have been substituted by other amino acid residues, said substitution being made without substantial loss of the basic structure and stability of the said B or Z domain, and said substitution resulting in interaction capacity of the said polypeptide with at least one domain of human Factor VIII protein.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

**DERIVATIVES OF THE B OR Z DOMAIN FROM STAPHYLOCOCCAL PROTEIN A (SPA) INTERACTING WITH AT LEAST ONE DOMAIN OF HUMAN FACTOR VIII****TECHNICAL FIELD**

5 The present invention relates to polypeptides which are derivatives of a staphylococcal protein A (SPA) domain, more specifically the B or Z domain, wherein between 1 and 20 amino acid residues of the said SPA domain have been substituted by other amino acid residues, said substitution resulting in interaction capacity of the said polypeptide with human Factor VIII protein. The said polypeptides are useful e.g. in the  
10 purification of Factor VIII protein and in diagnosis of hemophilia.

**BACKGROUND ART**

15 *Modified bacterial receptor structures*

Random mutagenesis in combination with an efficient phenotypic selection procedure has proved to be an important tool in molecular biology to analyze the structure and function of proteins. Interesting targets for random mutagenesis followed by phenotypic selection  
20 are solvent-exposed surfaces of bacterial receptors. Such proteins can be unusually stable, which makes them suitable for various applications (Alexander et al. (1992) Biochemistry 31, 3597-3603). In particular, for bacterial receptors containing helix bundle structures, the conformation can be expected to be tolerant to changes in the side chains of residues not involved in helix packing interfaces. Examples of such molecules are the relatively small  
25 (58 residues) IgG-binding domain B of staphylococcal protein A (SPA) and the synthetic analogue of domain B, designated domain Z (Nilsson et al. (1987) Protein Engineering 1, 107-113).

The SPA-derived domain Z (SEQ ID NO: 1) has been utilized as a scaffold for  
30 constructing domain variants with new functions. Repertoires of mutant Z domain genes were assembled and inserted into a phagemid vector adapted for monovalent phage display

of Z domain variants. Two combinatorial libraries, each comprising approximately  $4 \times 10^7$  transformants, were constructed. Selection against different target proteins, viz. *Taq* DNA polymerase, human insulin and a human apolipoprotein A-1 variant, was performed. The obtained binding proteins were referred to as "affibodies". See WO 95/19374; Nord et al. (1995) Protein Engineering, Vol. 8 (6), 601-608 (hereinafter referred to as Nord-95); and Nord et al. (1997) Nature Biotechnology, Vol. 15, 772-777 (hereinafter referred to as Nord-97).

### *Hemophilia and Factor VIII deficiency*

10

Hemophilia is an inherited disease which has been known for centuries, but it is only within the last four decades that it has been possible to differentiate between the various forms; hemophilia A and hemophilia B. Hemophilia A is the most frequent form. It affects only males with an incidence of one or two individuals per 10,000 liveborn males. The disease is caused by a strongly decreased level or absence of biologically active coagulation Factor VIII (also known as antihemophilic factor, AHF), which is a protein normally present in plasma.

15

Therapeutic Factor VIII concentrates for the treatment of hemophilia have been prepared by fractionation of plasma. Factor VIII concentrates derived from human plasma contain several fragmented fully active Factor VIII forms as described by Andersson et al. (1986) Proc. Natl. Acad. Sci. USA 83, 2979-2983. The smallest active form hitherto described has a molecular mass of 170 kDa and consists of two chains of 90 kDa and 80 kDa, respectively, held together by metal ion(s). Reference is here made to EP-A-0 197 901.

25

However, methods are also available for production of Factor VIII in cell culture using recombinant DNA techniques, as reported e.g. by Wood et al. (1984) Nature 312, 330-337 and in EP-A-0 160 457. The structure and biochemistry of recombinant Factor VIII products in general have been described by Kaufman, R.J. in Trends in Biotechnology Vol. 9(10), 353-359, 1991; and in Hematology Vol. 63, 155-165, 1991. A recombinant Factor

30

- 3 -

VIII form, termed r-VIII SQ, which corresponds to the 170 kDa plasma form, is described in WO 91/09122.

There is a need for new polypeptides which have interaction capacity with the Factor VIII protein and which can be used e.g. for purification of Factor VIII, for diagnosis of conditions related to Factor VIII deficiency, such as hemophilia, in therapy, or for research purposes.

## BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1

Amino acid sequences (one-letter code) of the Z domain derived from *Staphylococcus aureus* protein A ( $Z_{wt}$ ) and modified polypeptides (affibodies) according to the invention. The 13 positions chosen for random mutagenesis during construction of the combinatorial libraries are indicated with boldface letters.

Fig. 2

Sensorgrams from Biospecific Interaction Analysis of the affibody  $Z_{FVIII:3}$  (SEQ ID NO: 4) with Factor rVIII (panel A); the 80 kDa chain of Factor rVIII (panel B); and polyclonal human IgG (panel C).

Fig. 3

Overlay plot of sensorgrams from a competitive binding assay with affibody  $Z_{FVIII:3}$  (SEQ ID NO: 4) using the monoclonal antibody 8A4 as a competitor and polyclonal human IgG as a negative control competitor. Three different samples (Pure rVIII; rVIII mixed with mAb 8A4; and rVIII mixed with polyclonal IgG) were injected over the affibody surface.

Fig. 4

Sensorgrams from binding analysis of Factor VIII injected over a synthetic affibody (SEQ ID NO: 40) surface:

(A) Affibody binding to recombinant Factor VIII (rVIII);

5 (B) Affibody binding to blood plasma containing Factor VIII.

Fig. 5

Overlay plot of sensorgrams from binding analysis of recombinant Factor VIII (rVIII) with equimolar concentrations of second generation affibodies Z<sub>fVIII mat.26</sub> (SEQ ID NO: 33); Z<sub>fVIII mat.28</sub> (SEQ ID NO: 35) and Z<sub>fVIII mat.31</sub> (SEQ ID NO: 38), as well as  
10 the first generation affibody Z<sub>fVIII:3</sub> (SEQ ID NO: 4).

## DISCLOSURE OF THE INVENTION

15

The present invention provides modified polypeptides (affibodies) which have interaction capacity with Factor VIII protein and which can be used e.g. in methods for analysis of Factor VIII and purification of Factor VIII. The said affibodies could also be used e.g. as lead compounds for the identification of small molecules interacting  
20 with Factor VIII, said small molecules being potentially useful in therapy.

The polypeptides ("affibodies") according to the invention have several advantages over traditional antibodies, e.g. (i) a lower cost of manufacture; (ii) smaller size; (iii) increased stability and robustness; and (iv) the ability of being produced recombinantly  
25 in a bacterial host, or by chemical synthesis, which obviates the risk for viral contamination.

Consequently, in a first aspect, the present invention provides a polypeptide which is a derivative of a staphylococcal protein A (SPA) domain, said SPA domain being the B  
30 or Z domain, wherein a number of the amino acid residues have been substituted by other amino acid residues, said substitution being made without substantial loss of the

- 5 -

basic structure and stability of the said SPA domain, and said substitution resulting in interaction capacity of the said polypeptide with at least one domain of human Factor VIII protein. The number of substituted amino acid residues could be from 1 to about 20, or from 1 to about 13. Other possible ranges are from 4 to about 20; from 4 to about 13; from 5 to about 20, or from 5 to about 13 amino acid residues. It will be understood by the skilled person, e.g. from the references Nord-95 and Nord-97, that preferentially amino residues located on the surface of the Z-domain can be substituted, while the core of the bundle should be kept constant to conserve the structural properties of the molecule.

In the present context the term "derivative" includes polypeptides having additional amino acid residues at the N- or C-terminal end. Additional amino acid residues could be included for various reasons concerning production, purification or stabilization, such as e.g. for facilitated coupling to chromatographic resins. The invention thus includes polypeptides (affibodies) which are longer than the SPA domain from which they are derived, but which still have interaction capacity with Factor VIII.

The said SPA domain Z has preferably the amino acid sequence set forth as SEQ ID NO: 1. However, the term "domain Z" also includes variants of domain Z having essentially the same basic structure and stability as the SPA domain Z.

Preferably, at least 4 amino acid residues of the said SPA domain have been substituted by other amino acid residues. The substituted amino acid residues can e.g. be those in positions 9, 10, 13 and 14, or positions 9, 10, 13, 14 and 17, in SEQ ID NO: 1. In addition, one or more of the amino acid residues in positions 11, 18, 24, 25, 27, 28, 32 and 35 in SEQ ID NO: 1 can be substituted by other amino acid residues. As indicated above, it will be understood that other amino acid residues can be substituted provided that the basic structural properties of the domain Z are maintained.

In a particularly preferred form, the invention includes polypeptides wherein the amino acid residue in position 9 in SEQ ID NO: 1 has been substituted by a tryptophane (W)

– 6 –

residue; position 10 by an arginine (R) residue, position 13 by a tryptophane (W) residue and position 14 by a valine (V) residue.

The invention also includes polypeptides wherein the amino acid residue in position 17 in SEQ ID NO: 1 has been substituted by an arginine (R), glycine (G), alanine (A) or, preferably, a lysine (K) residue; as well as polypeptides wherein the amino acid residue in position 35 in SEQ ID NO: 1 has been substituted by a glycine (G), tryptophane (W), arginine (R), tyrosine (Y), valine (V), phenylalanine (F) or, preferably, leucine (L) residue.

The term “domain of human Factor VIII protein” includes in particular the 90 kDa and 80 kDa domains. Polypeptides according to the invention, wherein the Factor VIII domain is the 90 kDa domain, could e.g. have the amino acid sequence set forth in any one of SEQ ID NOS: 2 to 6, or 8 to 39. A polypeptide according to the invention, wherein the Factor VIII domain is the 80 kDa domain, could e.g. have the amino acid sequence set forth in SEQ ID NO: 7.

In a further aspect, the invention provides a process for the manufacture of a polypeptide (affibody) as defined above, said process comprising the steps

- (i) displaying, by e.g. phage display (for a review, see e.g. Kay, K. et al. (eds.) Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, San Diego, ISBN 0-12-402380-0), ribosomal display (for a review, see e.g. Hanes, J. et al. (1998) Proc. Natl. Acad. Sci. USA 95(24), 14130-14135) or cell display (for a review, see e.g. Daugherty, P.S. et al. (1998) Protein Eng. 11(9), 825-832), polypeptide variants from a protein library embodying a repertoire of polypeptide variants derived from SPA domain B or Z;
- (ii) selecting clones expressing polypeptides that bind to human Factor VIII protein; and
- (iii) producing polypeptides by recombinant expression of the selected clones or by chemical synthesis.



- 7 -

The said SPA domain is preferably the Z domain having, as discussed above, essentially the amino acid sequence set forth as SEQ ID NO: 1. The various steps of the process can be performed by the skilled person by methods disclosed in the present description, in particular in the following examples, and by methods known in the art.

5

In yet another aspect, the invention provides a method for purification of human Factor VIII protein, comprising interaction of a polypeptide (affibody), as defined above, with the said human Factor VIII protein. Such a method could e.g. comprise the steps

- (a) coupling a polypeptide (affibody) according to the invention to a matrix, said  
10 matrix being prepared from e.g. sepharose, silica, cellulose or membranes.
- (b) contacting a sample containing human Factor VIII protein to the matrix, so that said human Factor VIII protein interacts with the said polypeptide;
- (c) washing the matrix under conditions, such as the conditions described in Example 6, below, suitable for maintaining the interaction between human Factor VIII protein  
15 and the affibody; and
- (d) recovering biologically active human Factor VIII protein, by e.g. elution with ethylene glycol.

The said human Factor VIII protein can be derived from human plasma or produced by  
20 recombinant DNA techniques well known in the art. The term "Factor VIII protein" is intended to include derivatives having essentially the biological functions of wild-type Factor VIII. Such a Factor VIII derivative could e.g. be a deletion derivative lacking one or more amino acids in the region between amino acids 740 and 1649 (the B domain), as disclosed in WO 91/09122. Other Factor VIII derivatives are disclosed in  
25 WO 92/16557. It will be understood that the part of the Factor VIII protein interacting with the affibody could be the 90 kDa or the 80 kDa domain, depending on the specificity of the used affibody.

## EXAMPLES

5    Example 1. Construction of libraries

The previously described libraries Z-lib1 and Z-lib2 (Nord-95 and Nord-97), based on the synthetic 58-residue SPA domain Z (Nilsson et al. (1987) Protein Engineering 1, 107-113), were used for selection of novel binding proteins directed against  
10    recombinant Factor VIII (hereinafter also referred to as rVIII). In the construction of the Z domain libraries, 13 surface located residues (Q9, Q10, N11, F13, Y14, L17, H18, E24, E25, R27, N28, Q32 and K35) in helices 1 and 2 of the three helix bundle Z domain were targeted for randomization using a NN(G/T) codon degeneracy in Z-lib1 and a (C/A/G)NN degeneracy in Z-lib2. The libraries were adopted for monovalent  
15    display on filamentous bacteriophage surfaces through fusion to a truncated version of phage coat protein 3.

Phage stocks for biopanning rounds were prepared using standard procedures involving helper phage M13K07 (New England Biolabs, Beverly, MA) routinely yielding titers in  
20    the range of  $10^{11}$  to  $10^{12}$  colony forming units per ml, after polyethylene glycol precipitation.

Example 2. Selection of first generation affibodies

## 25    (a) Biotinylation and immobilization of recombinant Factor VIII

The target protein, recombinant Factor VIII with the B-domain deleted (hereinafter referred to as rVIII) was obtained essentially as described in WO 91/09122 and *in vitro* biotinylated in order to enable a robust immobilization onto streptavidin coated  
30    paramagnetic beads for the biopanning procedure, using a biotinylation kit (EZ-Link™; Sulfo-NHS-LC-Biotin, prod no. 21335, Pierce Chemical Company, Rockford, IL).

Approximately 100 µg of the *in vitro* biotinylated rVIII was mixed with 5 mg of pre-washed (according to the suppliers recommendations) streptavidin coated paramagnetic beads (SA beads) (Dynabeads M-280 Streptavidin, Dynal AS, Oslo, Norway) in a final volume of 1 ml binding buffer (0.1 M ammonium acetate, 5 mM calcium chloride, 0.8 M sodium chloride, 0.02% Tween-20, pH 6.1), and incubated on a rotator for 1 hour at room temperature and 2 hours at +4°C. The SA beads with the immobilized rVIII were subsequently washed six times with binding buffer. This procedure resulted in the immobilization of approximately 10 µg of the 90 kDa chain of rVIII per 5 mg of SA beads, as determined by SDS-PAGE analysis.

#### (b) Biopanning

Four rounds of biopanning (affinity-based selection), in the presence of a five-fold molar excess of the 80 kDa chain of rVIII in solution (in order to eliminate most of the potential 80 kDa chain binders), with increasing amounts of washing in each cycle were performed. Elutions with low pH and ethylene glycol were performed in parallel biopannings.

Biopanning was performed as follows: In the first cycle, 100 µl phage stock from either Z-lib1 or Z-lib2, 90 µl of the 80 kDa chain of rVIII in solution (approximately 2.5 µM) and 10 µl 2% gelatin solution were added to two tubes of dry SA beads with immobilized rVIII and incubated on a rotator at room temperature for two hours. The SA beads were washed once with binding buffer (5 minutes washing time) and bound phage particles were subsequently eluted with 0.5 ml glycine-HCl, pH 2.2 for 10 minutes at room temperature. The supernatants were immediately neutralized with 50 µl of 1 M Tris-Cl, pH 8.5. Eluted phage particles were used to infect 1 ml of log phase ( $A_{600} \approx 1$ ) *E. coli* RR1ΔM15 cells (Rüther (1982) Nucleic Acid Research 10, 5765-5772) for 20 min at +37°C and were thereafter spread onto TYE (per liter: 15 g agar, 8 g BaCl, 10 g Tryptone and 5 g yeast extract) agar plates supplemented with glucose 2% and ampicillin (100 mg/l), for the preparation of new phage stocks.

In the second cycle, two tubes of SA beads containing biotinylated rVIII were incubated with 50 µl phage stock from the biopanning with Z-lib1 mixed with 50 µl phage stock from the biopanning with Z-lib2 in the first cycle. Otherwise, conditions were the same as in the first cycle. The SA beads were washed three times with binding  
5 buffer and twice with washing buffer (50 mM calcium chloride, 50 mM histidine, 0.05% Tween-20, pH 6.6) (25 min. total washing time). One of the tubes was eluted with glycine-HCl, pH 2.2, as before, but for 20 min., and the other tube was eluted with elution buffer (50 mM calcium chloride, 50 mM histidine, 0.02% Tween-20, 50% ethylene glycol, pH 6.6) for 20 min. at room temperature.

10

In the third cycle, the conditions were the same as in cycle two, except that the phage stock input in one tube was prepared from the eluted phage from the pH 2.2 elution in the previous cycle, and the input in the other tube was prepared from the ethylene glycol elution. The SA beads were washed five times with binding buffer and five  
15 times with washing buffer (approximately 1 hour total washing time). The elution was done as before with pH 2.2 elution in the tube with the pH 2.2 eluted input phage stock and ethylene glycol elution in the tube with the ethylene glycol eluted input phage stock. Cycle four was performed exactly as cycle three.

20 The eluted phages from each panning round were titrated by infecting log phase RR1ΔM15 cells (OD at 600 nm  $\approx$  0.5) with serial dilutions of the eluate at +37°C for 20 min. The rest of the eluted phages were used to infect 10 ml of the cells. The cells were spread on TYE agar plates supplemented with 2% glucose and 100 µg/ml ampicillin and the plates were incubated at +37°C over night. The colonies were  
25 collected and used to inoculate TSB supplemented with 1% glucose and 100 µg/ml ampicillin, for preparation of a new phage stock for the next round of panning. After the last panning round, reinfected cells were spread on plates to yield clones for DNA sequence analysis of selected Z domain variants.

30 (c) DNA sequencing

Solid phase sequencing (Hultman et al. (1989) Nucleic Acid Research 17, 4937-4946) of twenty of the selected affibody clones from the fourth cycle (ten from the elution with pH 2.2 and ten from the elution with ethylene glycol) was performed by employing the indodicarbocyanine dye ALFred (Cy5) phosphoramidite labeled sequencing primer NOKA-3 on a robotic workstation (Biomek 1000, Beckman Instruments, Fullerton, CA). The Sanger-fragments were analyzed on an ALFexpress™ (Amersham Pharmacia Biotech, Uppsala, Sweden). Nine different sequences were identified, some represented by more than one clone.

10 Example 3. Production and purification of first generation affibodies

Nine different affibodies, identified in the DNA sequencing step, were produced as soluble secreted proteins, fused to a 5 kDa serum albumin binding domain (ABD) from staphylococcal protein G (SPG) (Nilsson et al. (1994) Eur. J. Biochem. 224, 103-108), as encoded from the phagemid vector (Nord-97), in a non-suppressor strain, *E. coli* RV308 (Maurer et al. (1980) J. Mol. Biol. 139, 147-161). The affibody-ABD fusion proteins were released from the periplasm and purified by affinity chromatography on an HSA-Sepharose column (Nygren et al. (1988) J. Mol. Recogn. 1, 69-74) and expression levels in this expression system were in the range of 10 mg/l shake flask culture.

Example 4. Biospecific interaction analysis of first generation affibodies

A BIAcore® 2000 instrument (Biacore AB, Uppsala, Sweden) was employed for real-time Biospecific Interaction Analysis (BIA) of the interaction between selected variants and rVIII. The ligands were immobilized by amine coupling onto the carboxylated dextran layer of a CM5 sensor chip (research grade) (Biacore AB) according to the manufacturer's recommendations. All analyses were performed at +25°C, the flow rate was 5 µl/min and the injected sample volume was 35 µl, unless otherwise stated. The surfaces were regenerated with 10 µl 10 mM NaOH, 1 M NaCl.

Injection of (i) rVIII, (ii) the 80 kDa chain of rVIII, or (iii) as a control polyclonal human IgG, over sensor chip surfaces coated with 1000 to 2500 resonance units (RU) of the selected affibody variants, demonstrated a significant response only for rVIII (80 + 90 kDa chain variant) for five of the affibodies ( $Z_{\text{FVIII}:1}$  to  $Z_{\text{FVIII}:5}$ ; SEQ ID NOS: 2 to 6), indicating that the binding is directed to the 90 kDa chain of rVIII and that the affinity towards IgG (Fc), displayed by the parental Z domain, is lost as expected. Fig. 2 shows the results obtained with affibody  $Z_{\text{FVIII}:3}$  (SEQ ID NO: 4).

For one of the affibodies ( $Z_{\text{FVIII}:6}$ ; SEQ ID NO: 7), a response was obtained both when injecting rVIII and the 80 kDa chain alone, indicating that the binding is directed to at least part of the 80 kDa chain of rVIII.

Four of the degenerated residues (W9, R10, W13 and V14) were conserved among all the 90 kDa chain binders and two of the residues showed a preference for either lysine or arginine (R/K17 and R/K27). There was also a preference for leucine in position 35.

For determination of kinetic parameters, the affibodies  $Z_{\text{FVIII}:1}$  to  $Z_{\text{FVIII}:4}$  (SEQ ID NOS: 2 to 5) were immobilized onto different surfaces as above. A control sensor chip surface was prepared by NHS/EDC-activation immediately followed by deactivation with ethanolamine. Recombinant Factor VIII was injected at 14 different concentrations (0.25 nM to 1.25  $\mu\text{M}$ ) in a volume of 100  $\mu\text{l}$  in random order over the surfaces at a flow rate of 20  $\mu\text{l}/\text{min}$ . After each injection, the surfaces were regenerated with 10 mM NaOH, 1 M NaCl. The rVIII responses were subtracted by the responses from the blank surface for each concentration and for each affibody surface. The dissociation and association rate constants were calculated using the BIA evaluation 2.1 software (BIAcore AB) according to the standard protocol for a one-to-one interaction model. The apparent overall dissociation constants ( $K_D$ ) for the investigated variants were calculated to the range  $1-2 \times 10^{-7} \text{ M}$ .

Example 5. Competitive binding assay (first generation affibodies)

– 13 –

In order to further localize the binding site for the affibodies on the 90 kDa chain of rVIII, a monoclonal antibody designated 8A4, having a previously mapped binding interaction with the 90 kDa chain of rVIII, was used. BIA analysis was performed and three different injections were made over the affibody surfaces: (a) pure rVIII (42 nM);  
5 (b) rVIII (42 nM) mixed with 17 nM mAb 8A4; and (c) as a control, rVIII (42 nM) mixed with a 26-fold molar excess (1.1  $\mu$ M) of polyclonal human IgG. The results, shown in Fig. 3, indicate a decrease in binding of rVIII to the affibody surfaces only when premixed with mAb 8A4, indicating that the affibody and mAb 8A4 compete for at least overlapping epitopes on rVIII.

10

#### Example 6. Affinity chromatography of Factor VIII on an affibody column

The affibody designated Z<sub>FVIII:3</sub> was coupled to a HiTrap<sup>®</sup> affinity column packed with 1 ml NHS-activated Sepharose<sup>®</sup> High Performance (Amersham Pharmacia  
15 Biotech, Uppsala, Sweden) according to the manufacturer's recommendations, resulting in approximately 2 mg of coupled Z<sub>FVIII:3</sub>-ABD fusion protein. The column was connected to an ÄKTA<sup>™</sup> explorer 10 system (Amersham Pharmacia Biotech, Uppsala, Sweden) and equilibrated with 5 column volumes of binding buffer (0.1 M ammonium acetate, 5 mM calcium chloride, 0.8 M sodium chloride, 0.02 % Tween-20,  
20 pH 6.1) before loading of the sample. One ml of sample containing rVIII (0.1 mg/ml in binding buffer) was applied onto the column with a flow rate of 1 ml per minute. After washing with three column volumes of binding buffer and four column volumes of washing buffer (50 mM calcium chloride, 50 mM histidine, 0.05% Tween-20, pH 6.6), the captured protein was eluted with either 0.3 M acetic acid, pH 3.2 or elution buffer  
25 (50 mM calcium chloride, 50 mM histidine, 0.02% Tween-20, 50% ethyleneglycol, pH 6.6) and monitored by UV detection at 280 nm. SDS-PAGE analysis of the eluted fractions showed highly purified rVIII.

#### Example 7. Factor VIII activity assay

30

A Factor VIII activity assay was performed to determine the content of rVIII in the sample loaded on the affinity column, the flow through fractions and the eluted fractions. The activity assay was performed essentially as described by Rosén (1984) J. Haematol. Vol. 33, Suppl. 40, 139-145; and by Carlebjörk et al. (1987) Thrombosis Research Vol. 47, 5-14.

In this assay, Factor Xa (activated Factor X) is generated via the intrinsic pathway where Factor VIII:C is acting as a co-factor. Factor Xa is then determined by the use of a synthetic chromogenic substrate in the presence of a thrombin inhibitor to prevent hydrolysis of the substrate by thrombin. The reaction is terminated with acid and the Factor VIII:C activity, which is proportional to the release of paranitroaniline (pNA), is determined photometrically at 405 nm.

The flow through fractions did not show any Factor VIII activity, while the eluted fractions did, indicating that the affibody column was capable of binding rVIII, which subsequently could be eluted in functional form.

#### Example 8. Binding studies using synthetic affibody

A synthetic affibody (SEQ ID NO: 40), based on Z<sub>FVIII:3</sub> (SEQ ID NO: 4) and having an extra cystein residue at the C-terminal end, was produced by peptide synthesis according to known methods. The synthetic affibody enabling directed coupling, via the cystein residue, onto a BIA sensor chip surface. The synthetic affibody was thus immobilized by ligand thiol coupling onto the carboxylated dextran layer of a CM5 sensor chip (research grade) (Biacore AB) according to the manufacturer's recommendations and resulted in the immobilization of 450 RU. A control surface was prepared by activation followed by deactivation. The analyses were performed at +25°C, the flow rate was 5 µl/min, the injected sample volume was 25 µl and the regeneration was performed with 0.05% SDS. rVIII was injected over the surfaces and the rVIII response was subtracted by the response from the blank surface. A significant



– 15 –

response was obtained (Fig. 4a), indicating that the affibody had been successfully synthesized and was correctly folded.

Plasma-derived Factor VIII (Octonativ-M, Pharmacia & Upjohn AB) was used in the binding study (Nilsson et al. pp. 193-206 In: Smith Sibinga et al. (eds.) Coagulation and Blood Transfusion (Proc. Fifteenth Ann. Symp. Blood Transfusion, Groningen 1990) Kluwer Academic Publishers, 1991). The plasma-derived Factor VIII was purified using immunoaffinity and ion-exchange chromatography essentially according to "Method M" (Griffith, M. (1991) Ann Hematol. 63, 131-137).

10

A sample containing purified plasma-derived Factor VIII was injected over the same surfaces under the same conditions as above (Fig. 4b). The difference in binding profile from rVIII can be due to the occurrence of different forms of Factor VIII in plasma, in addition to the association of Factor VIII with von Willebrand's factor.

15

A negative control experiment where the blood plasma was injected over wild-type Z (SEQ ID NO: 1) did not result in any response, indicating that the synthetic affibody bound specifically to factor VIII in the plasma.

20 Example 9. Construction of a second generation library for selection of rVIII-specific affibodies with improved affinities

A second generation combinatorial library of SPA domain Z sequences was prepared, as essentially described in Example 1, for selection of improved binding (affinity matured) polypeptides directed to recombinant Factor VIII. Five of the 13 residues in the second generation library were fixed; tryptophan, arginine, tryptophan, valine and arginine in residues 9, 10, 13, 14 and 27, respectively, while in residue number 17, the amino acid was fixed to either lysine or arginine by an A(A/G)G degeneracy codon. The remaining 7, of the 13 surface located residues, were targeted for re-randomization using NN(G/T) degeneracy, as for the native library.

30

Example 10. Selection of second generation affibodies

Biopanning against rVIII using the constructed second generation library, was performed with biotinylated rVIII immobilized on streptavidin coated paramagnetic beads, as described in Example 2. The rounds of biopanning were performed with an excess of the 80 kDa chain from Factor VIII, as in Example 2, in order to eliminate most of the potential 80 kDa binders. Increasing stringency throughout the panning cycles was achieved with an extended number of washing steps and a decreased amount of immobilized rVIII. All elution steps were performed with 50% ethylene glycol.

DNA sequencing of the phagemid inserts in 18 clones from panning cycle 4, 10 clones from cycle 5, and 8 clones from cycle 6, revealed that two pairs of clones were identical. The selected affibodies having unique sequences are shown in Fig.1 and in the Sequence Listing as SEQ ID NOS: 8 to 22 (cycle 4); SEQ ID NOS: 23 to 31 (cycle 5) and SEQ ID NOS: 32 to 39 (cycle 6).

Some analogy with respect to amino acid type was detected in the 8 selected clones from panning cycle 6 (SEQ ID NOS: 32 to 39). Positions 24, 32 and 35 all contained a hydrophobic amino acid; there was a preference for aspartic or glutamic acid in position 28; and position 17 was conserved to lysine (see Fig. 1).

The selected affibodies from cycle 6 were produced from their phagemid constructs as described in Example 3.

Example 11. Binding studies using second generation affibodies

For ranking of the selected second generation affibodies, real time Biospecific Interaction Analysis (BIA) was used. A chip surface was immobilized with human serum albumin (HSA) and the affibodies were injected individually at a concentration of 1.4  $\mu$ M over the HSA-surface, followed by injection of rVIII (30 nM). One of the

first generation affibodies,  $Z_{\text{rVIII}:3}$ , was included in the ranking for comparison. All of the eight second generation affibodies showed a greater affinity towards rVIII compared to the  $Z_{\text{rVIII}:3}$  affibody. Fig. 5 illustrates the results obtained with affibodies  $Z_{\text{rVIII mat.26}}$ ,  $Z_{\text{rVIII mat.28}}$  and  $Z_{\text{rVIII mat.31}}$ .

5

For calculation of kinetic parameters, rVIII was injected at 16 different concentrations over the surfaces with affibodies  $Z_{\text{rVIII mat.26}}$ ,  $Z_{\text{rVIII mat.28}}$  and  $Z_{\text{rVIII mat.31}}$ , respectively. The association and dissociation rates were determined, resulting in an apparent overall dissociation constant ( $K_D$ ) in the range of  $5-10 \times 10^{-9}$  M for the three

10 affibodies.

Two different monoclonal antibodies designated mAb 8A4 (having binding specificity for the 90 kDa chain of Factor VIII) and mAb 2B5 (having binding specificity for the 80 kDa chain of Factor VIII) were used for localization of the binding sites for the

15 three affibodies mentioned above. BIA analysis was performed and four different injections over the surfaces were made; pure rVIII, rVIII mixed with mAb 8A4, rVIII mixed with mAb 2B5 and rVIII mixed with polyclonal human IgG. The results indicate an increase in binding of rVIII mixed with mAb 2B5 and a decrease in binding of rVIII mixed with mAb 8A4 to all three affibody surfaces. The increased signal seen with

20 mAb 2B5 is explained by the presence on rVIII of separate epitopes for mAb 2B5 and the affibody, which means that rVIII binds simultaneously to these two entities which increases the mass of the bound complex. Furthermore, there was no obvious difference between the binding of pure rVIII compared to the binding of rVIII mixed with polyclonal human IgG to the affibody surfaces. Thus, the second generation

25 affibodies bind to the 90 kDa chain of rVIII, as expected, and the mAb 8A4 and the affibodies compete for at least overlapping epitopes on rVIII.

## SEQUENCE LISTING FREE TEXT

In the Sequence Listing placed at the end of this patent specification, the following  
“Free text” is included for SEQ ID NOS: 2 to 40 under numeric identifier <223>

- 5 (Other information): “Description of Artificial Sequence: Modified bacterial receptor  
sequence”

## CLAIMS

1. A polypeptide which is a derivative of a staphylococcal protein A (SPA) domain, said SPA domain being the B or Z domain, wherein between 1 and 20 amino acid  
5 residues of the said SPA domain have been substituted by other amino acid residues, said substitution being made without substantial loss of the basic structure and stability of the said SPA domain, and said substitution resulting in interaction capacity of the said polypeptide with at least one domain of human Factor VIII protein.
- 10 2. A polypeptide according to claim 1 which is a derivative of the SPA domain Z having the amino acid sequence set forth as SEQ ID NO: 1, or a polypeptide which is a derivative of a variant of the said SPA domain Z, said variant having essentially the same basic structure and stability as the SPA domain Z.
- 15 3. A polypeptide according to claim 1 or 2 wherein at least 4 amino acid residues of the said SPA domain have been substituted by other amino acid residues.
4. A polypeptide according to claim 2 or 3 wherein at least the amino acid residues in  
20 positions 9, 10, 13 and 14 in SEQ ID NO: 1 have been substituted by other amino acid residues.
5. A polypeptide according to any one of claims 2 to 4 wherein at least the amino acid residues in positions 9, 10, 13, 14 and 17 in SEQ ID NO: 1 have been  
25 substituted by other amino acid residues.
6. A polypeptide according to claim 4 or 5 wherein, in addition, one or more of the amino acid residues in positions 11, 18, 24, 25, 27, 28, 32 and 35 in SEQ ID NO: 1 have been substituted by other amino acid residues.

– 20 –

7. A polypeptide according to any one of claims 1 to 6 wherein the said domain of human Factor VIII protein is the 90 kDa domain.
8. A polypeptide according to any one of claims 2 to 7 wherein the amino acid  
5 residue in position 9 in SEQ ID NO: 1 has been substituted by a tryptophane (W) residue; position 10 by an arginine (R) residue, position 13 by a tryptophane (W) residue and position 14 by a valine (V) residue.
9. A polypeptide according to any one of claims 2 to 8 wherein the amino acid  
10 residue in position 17 in SEQ ID NO: 1 has been substituted by an arginine (R), lysine (K), glycine (G), or alanine (A) residue.
10. A polypeptide according to any one of claims 2 to 9 wherein the amino acid  
15 residue in position 35 in SEQ ID NO: 1 has been substituted by a glycine (G), tryptophane (W), leucine (L), arginine (R), tyrosine (Y), valine (V), or phenylalanine (F) residue.
11. A polypeptide according to claim 9 wherein the amino acid residue in position 17  
20 in SEQ ID NO: 1 has been substituted by a lysine (K) residue.
12. A polypeptide according to claim 10 wherein the amino acid residue in position 35  
in SEQ ID NO: 1 has been substituted by a leucine (L) residue.
13. A polypeptide according to any one of claims 1 to 10 having the amino acid  
25 sequence set forth in any one of SEQ ID NOS: 2 to 6, or 8 to 40.
14. A polypeptide according to any one of claims 1 to 6 wherein the said domain of human Factor VIII protein is the 80 kDa domain.
- 30 15. A polypeptide according to claim 14 having the amino acid sequence set forth in SEQ ID NO: 7.

16. A process for the manufacture of a polypeptide according to any one of claims 1 to 15, comprising the steps
- (i) displaying polypeptide variants from a protein library embodying a repertoire of polypeptide variants derived from SPA domain B or Z;
  - (ii) selecting clones expressing polypeptides that bind to human Factor VIII protein; and
  - (iii) producing polypeptides by recombinant expression of the selected clones or by chemical synthesis.
17. A method for purification of human Factor VIII protein, comprising interaction of a polypeptide according to any one of claims 1 to 15 with the said human Factor VIII protein.
18. The method according to claim 17, comprising the steps
- (a) coupling a polypeptide according to any one of claims 1 to 15 to a matrix;
  - (b) contacting a sample containing human Factor VIII protein to the matrix, so that said human Factor VIII protein interacts with the said polypeptide;
  - (c) washing the said matrix; and
  - (d) recovering biologically active human Factor VIII protein.
19. The method according to claim 17 or 18 wherein the said human Factor VIII protein is derived from human plasma.
20. The method according to claim 17 or 18 wherein the said human Factor VIII protein is produced by recombinant DNA techniques.
21. The method according to claim 20 wherein the said human Factor VIII protein is a biologically active Factor VIII deletion derivative lacking one or more amino acids in the region between amino acids 740 and 1649.

– 22 –

22. The method according to claim 20 wherein the said polypeptide is interacting with the 90 kDa domain of the said human Factor VIII protein.
23. The method according to claim 20 wherein the said polypeptide is interacting with  
5 the 80 kDa domain of the said human Factor VIII protein.



Fig. 1

	10	20	30	40	50	
	123456789	123456789	123456789	123456789	123456789	123456789
Z <sub>wt</sub>	VDNKFNKEQQA	FYEILHLPNLNEEQ	RNAFIQSLKDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 1)
Z <sub>fvIII:1</sub>	VDNKFNKEWRA	AWVEIRGLPNLNWQ	QKAFIVSLGDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 2)
Z <sub>fvIII:2</sub>	VDNKFNKEWRD	AWVEIKYLPNLNV	TQREAFIESLWDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 3)
Z <sub>fvIII:3</sub>	VDNKFNKEWRK	AWVEIKVLPNLNE	SQKGAFIMSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 4)
Z <sub>fvIII:4</sub>	VDNKFNKEWRL	AWVEIRALPNLNP	TQREAFILSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 5)
Z <sub>fvIII:5</sub>	VDNKFNKEWRE	AWVEIGLLPNLNF	TQKAFIKSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 6)
Z <sub>fvIII:6</sub>	VDNKFNKEVIV	AVPEIAILPNLNPA	QRAAFIASLRDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 7)
Z <sub>fvIII mat.1</sub>	VDNKFNKEWRN	AWVEIKYLPNLNAA	QGAFISSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 8)
Z <sub>fvIII mat.2</sub>	VDNKFNKEWRG	AWVEIKGLPNLN	YAQQA FISSLLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 9)
Z <sub>fvIII mat.3</sub>	VDNKFNKEWRM	AWVEIKILPNLN	WWQDAFIRSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 10)
Z <sub>fvIII mat.4</sub>	VDNKFNKEWRR	AWVEIKALPNLN	WGQNAFITSLLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 11)
Z <sub>fvIII mat.5</sub>	VDNKFNKEWRR	AWVEIRNLPNLN	WVQSAFIDSLYDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 12)
Z <sub>fvIII mat.6</sub>	VDNKFNKEWRG	AWVEIKTLPNLN	HWQAAFIESLLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 13)
Z <sub>fvIII mat.7</sub>	VDNKFNKEWRG	AWVEIKTLPNLN	YWQDAFIASLVDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 14)
Z <sub>fvIII mat.8</sub>	VDNKFNKEWRV	SWVEIKELPNLN	WWQRAFIQSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 15)
Z <sub>fvIII mat.9</sub>	VDNKFNKEWRE	AWVEIKELPNLN	WWQRAFIQSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 16)
Z <sub>fvIII mat.10</sub>	VDNKFNKEWRL	AWVEIKDLPNLN	WRQDAFISSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 17)
Z <sub>fvIII mat.11</sub>	VDNKFNKEWRQ	AWVGIKKLPNLN	YWQDAFIQSLFDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 18)
Z <sub>fvIII mat.12</sub>	VDNKFNKEWRA	AWVEIKGLPNLN	RPQNAFIDSLYDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 19)
Z <sub>fvIII mat.13</sub>	VDNKFNKEWRE	AWVEIKNLPNLN	WRQDAFIVSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 20)
Z <sub>fvIII mat.14</sub>	VDNKFNKEWRA	AWVEIRELPNLN	FIQDAFIDSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 21)
Z <sub>fvIII mat.15</sub>	VDNKFNKEWRS	AWVEIKVLPNLN	WWQREAFIGSLDDPSQ	SANLLAEAKKL	NDAAQAPK	(SEQ ID NO: 22)

Fig. 1 (continued)

	10	20	30	40	50	
	123456789	123456789	123456789	123456789	123456789	123456789
Z <sub>wt</sub>	VDNKFNKE <b>QQNAFY</b> EILHLPNLN <b>EEQ</b> RNAFI <b>Q</b> SLKDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 1)				
Z <sub>fVIII</sub> mat. 16	VDNKFNKE <b>WRLAW</b> VEIKGLPNLN <b>WAQ</b> RAFI <b>D</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 23)				
Z <sub>fVIII</sub> mat. 17	VDNKFNKE <b>WRTAW</b> VEIKDLPNLN <b>YYQ</b> RNAFI <b>E</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 24)				
Z <sub>fVIII</sub> mat. 18	VDNKFNKE <b>WRTAW</b> VEIKSLPNLN <b>FGQ</b> RRAFI <b>D</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 25)				
Z <sub>fVIII</sub> mat. 19	VDNKFNKE <b>WREAW</b> VEIKRLLPNLN <b>FEQ</b> RAFI <b>G</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 26)				
Z <sub>fVIII</sub> mat. 20	VDNKFNKE <b>WRQAW</b> VEIRGLPNLN <b>WWQ</b> RAFI <b>E</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 27)				
Z <sub>fVIII</sub> mat. 21	VDNKFNKE <b>WRDAW</b> VEIKSLPNLN <b>WFQ</b> RAFI <b>A</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 28)				
Z <sub>fVIII</sub> mat. 22	VDNKFNKE <b>WREAW</b> VEIKRLLPNLN <b>WYQ</b> RAFI <b>Y</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 29)				
Z <sub>fVIII</sub> mat. 23	VDNKFNKE <b>WRTAW</b> VEIKLLPNLN <b>WNQ</b> RAAFI <b>D</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 30)				
Z <sub>fVIII</sub> mat. 24	VDNKFNKE <b>WRLAW</b> VEIKHLPNLN <b>WWQ</b> RAFI <b>R</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 31)				
Z <sub>fVIII</sub> mat. 25	VDNKFNKE <b>WREAW</b> VEIKQLPNLN <b>WWQ</b> REAFI <b>G</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 32)				
Z <sub>fVIII</sub> mat. 26	VDNKFNKE <b>WRMAW</b> VEIKLLPNLN <b>YFQ</b> RAFI <b>M</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 33)				
Z <sub>fVIII</sub> mat. 27	VDNKFNKE <b>WRAAW</b> VEIKRLLPNLN <b>WMQ</b> RAFI <b>V</b> SLYDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 34)				
Z <sub>fVIII</sub> mat. 28	VDNKFNKE <b>WRDAW</b> VEIKTLPNLN <b>WYQ</b> RAFI <b>G</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 35)				
Z <sub>fVIII</sub> mat. 29	VDNKFNKE <b>WREAW</b> VEIKNLPNLN <b>WRQ</b> RAFI <b>G</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 36)				
Z <sub>fVIII</sub> mat. 30	VDNKFNKE <b>WRKAW</b> VEIKTLPNLN <b>WRQ</b> RAFI <b>L</b> SLYDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 37)				
Z <sub>fVIII</sub> mat. 31	VDNKFNKE <b>WRVAW</b> VEIKNLPNLN <b>WVQ</b> REAFI <b>G</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 38)				
Z <sub>fVIII</sub> mat. 32	VDNKFNKE <b>WRAAW</b> VEIKRLLPNLN <b>WMQ</b> RAFI <b>V</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 39)				
	VDNKFNKE <b>WRKAW</b> VEIKVLPNLN <b>ESQ</b> GAFI <b>M</b> SLDDPSQSANLLAEAKKLNDAAQAPK	(SEQ ID NO: 40)				

Fig. 2




Fig. 3




Fig. 4A




Fig. 4B





Fig. 5



- 1 -

## SEQUENCE LISTING

&lt;110&gt; Pharmacia &amp; Upjohn AB

&lt;120&gt; Receptor structures

&lt;130&gt; Modified polypeptides

&lt;160&gt; 40

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Staphylococcus aureus

&lt;400&gt; 1

Val	Asp	Asn	Lys	Phe	Asn	Lys	Glu	Gln	Gln	Asn	Ala	Phe	Tyr	Glu	Ile
1				5					10					15	

Leu	His	Leu	Pro	Asn	Leu	Asn	Glu	Glu	Gln	Arg	Asn	Ala	Phe	Ile	Gln
			20				25						30		

Ser	Leu	Lys	Asp	Asp	Pro	Ser	Gln	Ser	Ala	Asn	Leu	Leu	Ala	Glu	Ala
		35					40					45			

Lys	Lys	Leu	Asn	Asp	Ala	Gln	Ala	Pro	Lys
	50					55			

&lt;210&gt; 2

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 2

Val	Asp	Asn	Lys	Phe	Asn	Lys	Glu	Trp	Arg	Ala	Ala	Trp	Val	Glu	Ile
1				5					10					15	

Arg	Gly	Leu	Pro	Asn	Leu	Asn	Trp	Gln	Gln	Arg	Lys	Ala	Phe	Ile	Val
			20				25						30		

Ser	Leu	Gly	Asp	Asp	Pro	Ser	Gln	Ser	Ala	Asn	Leu	Leu	Ala	Glu	Ala
		35					40					45			

Lys	Lys	Leu	Asn	Asp	Ala	Gln	Ala	Pro	Lys
	50					55			

&lt;210&gt; 3

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence



- 2 -

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 3

Val	Asp	Asn	Lys	Phe	Asn	Lys	Glu	Trp	Arg	Asp	Ala	Trp	Val	Glu	Ile
1				5					10					15	

Lys	Tyr	Leu	Pro	Asn	Leu	Asn	Val	Thr	Gln	Arg	Glu	Ala	Phe	Ile	Glu
			20					25					30		

Ser	Leu	Trp	Asp	Asp	Pro	Ser	Gln	Ser	Ala	Asn	Leu	Leu	Ala	Glu	Ala
		35					40					45			

Lys	Lys	Leu	Asn	Asp	Ala	Gln	Ala	Pro	Lys
	50					55			

&lt;210&gt; 4

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 4

Val	Asp	Asn	Lys	Phe	Asn	Lys	Glu	Trp	Arg	Lys	Ala	Trp	Val	Glu	Ile
1				5					10					15	

Lys	Val	Leu	Pro	Asn	Leu	Asn	Glu	Ser	Gln	Lys	Gly	Ala	Phe	Ile	Met
			20					25					30		

Ser	Leu	Leu	Asp	Asp	Pro	Ser	Gln	Ser	Ala	Asn	Leu	Leu	Ala	Glu	Ala
		35					40					45			

Lys	Lys	Leu	Asn	Asp	Ala	Gln	Ala	Pro	Lys
	50					55			

&lt;210&gt; 5

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 5

Val	Asp	Asn	Lys	Phe	Asn	Lys	Glu	Trp	Arg	Leu	Ala	Trp	Val	Glu	Ile
1				5					10					15	

Arg	Ala	Leu	Pro	Asn	Leu	Asn	Pro	Thr	Gln	Arg	Glu	Ala	Phe	Ile	Leu
			20					25					30		

- 3 -

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

&lt;210&gt; 6

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 6

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
1 5 10 15

Gly Leu Leu Pro Asn Leu Asn Phe Thr Gln Gly Lys Ala Phe Ile Lys  
20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

&lt;210&gt; 7

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 7

Val Asp Asn Lys Phe Asn Lys Glu Val Ile Val Ala Val Pro Glu Ile  
1 5 10 15

Ala Ile Leu Pro Asn Leu Asn Pro Ala Gln Arg Ala Ala Phe Ile Ala  
20 25 30

Ser Leu Arg Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

&lt;210&gt; 8

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

- 4 -

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 8

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Asn Ala Trp Val Glu Ile  
1 5 10 15

Lys Tyr Leu Pro Asn Leu Asn Ala Ala Gln Arg Gly Ala Phe Ile Ser  
20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

&lt;210&gt; 9

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 9

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Gly Ala Trp Val Glu Ile  
1 5 10 15

Lys Gly Leu Pro Asn Leu Asn Tyr Ala Gln Arg Gln Ala Phe Ile Ser  
20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

&lt;210&gt; 10

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

&lt;400&gt; 10

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Met Ala Trp Val Glu Ile  
1 5 10 15

Lys Ile Leu Pro Asn Leu Asn Trp Trp Gln Arg Asp Ala Phe Ile Arg  
20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45

- 5 -

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
           50                          55

&lt;210&gt; 11

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
           bacterial receptor sequence

&lt;400&gt; 11

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Arg Ala Trp Val Glu Ile  
   1                          5                          10                          15

Lys Ala Leu Pro Asn Leu Asn Trp Gly Gln Arg Asn Ala Phe Ile Thr  
                           20                          25                          30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
           35                          40                          45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
           50                          55

&lt;210&gt; 12

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
           bacterial receptor sequence

&lt;400&gt; 12

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Arg Ala Trp Val Glu Ile  
   1                          5                          10                          15

Arg Asn Leu Pro Asn Leu Asn Trp Val Gln Arg Ser Ala Phe Ile Asp  
                           20                          25                          30

Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
           35                          40                          45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
           50                          55

&lt;210&gt; 13

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
           bacterial receptor sequence

- 6 -

&lt;400&gt; 13

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Gly Ala Trp Val Glu Ile  
 1 5 10 15

Lys Thr Leu Pro Asn Leu Asn His Trp Gln Arg Ala Ala Phe Ile Glu  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 14

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 14

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Gly Ala Trp Val Glu Ile  
 1 5 10 15

Lys Thr Leu Pro Asn Leu Asn Tyr Trp Gln Arg Asp Ala Phe Ile Ala  
 20 25 30

Ser Leu Val Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 15

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 15

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Val Ser Trp Val Glu Ile  
 1 5 10 15

Lys Glu Leu Pro Asn Leu Asn Trp Trp Gln Arg Arg Ala Phe Ile Gln  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

- 7 -

<210> 16  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

<400> 16

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
 1 5 10 15

Lys Glu Leu Pro Asn Leu Asn Trp Trp Gln Arg Arg Ala Phe Ile Gln  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

<210> 17  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

<400> 17

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Leu Ala Trp Val Glu Ile  
 1 5 10 15

Lys Asp Leu Pro Asn Leu Asn Trp Arg Gln Arg Asp Ala Phe Ile Ser  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

<210> 18  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

- 8 -

&lt;400&gt; 18

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Gln Ala Trp Val Gly Ile  
 1 5 10 15

Lys Lys Leu Pro Asn Leu Asn Tyr Trp Gln Arg Asp Ala Phe Ile Gln  
 20 25 30

Ser Leu Phe Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 19

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 19

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Ala Ala Trp Val Glu Ile  
 1 5 10 15

Lys Gly Leu Pro Asn Leu Asn Arg Pro Gln Arg Asn Ala Phe Ile Asp  
 20 25 30

Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 20

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 20

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
 1 5 10 15

Lys Asn Leu Pro Asn Leu Asn Trp Arg Gln Arg Asp Ala Phe Ile Val  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

- 9 -

<210> 21  
<211> 58  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

<400> 21  
Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Ala Ala Trp Val Glu Ile  
1 5 10 15  
Arg Glu Leu Pro Asn Leu Asn Phe Ile Gln Arg Asp Ala Phe Ile Asp  
20 25 30  
Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45  
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

<210> 22  
<211> 58  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

<400> 22  
Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Ser Ala Trp Val Glu Ile  
1 5 10 15  
Lys Val Leu Pro Asn Leu Asn Trp Trp Gln Arg Glu Ala Phe Ile Gly  
20 25 30  
Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45  
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

<210> 23  
<211> 58  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence



- 10 -

&lt;400&gt; 23

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Leu Ala Trp Val Glu Ile  
 1 5 10 15

Lys Gly Leu Pro Asn Leu Asn Trp Ala Gln Arg Gln Ala Phe Ile Asp  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 24

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 24

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Thr Ala Trp Val Glu Ile  
 1 5 10 15

Lys Asp Leu Pro Asn Leu Asn Tyr Tyr Gln Arg Asn Ala Phe Ile Glu  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 25

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 25

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Thr Ala Trp Val Glu Ile  
 1 5 10 15

Lys Ser Leu Pro Asn Leu Asn Phe Gly Gln Arg Arg Ala Phe Ile Asp  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

- 11 -

<210> 26  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

<400> 26  
 Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
   1                  5                  10                  15  
 Lys Arg Leu Pro Asn Leu Asn Phe Glu Gln Arg Gly Ala Phe Ile Gly  
                   20                  25                  30  
 Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
           35                  40                  45  
 Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
   50                  55

<210> 27  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

<400> 27  
 Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Gln Ala Trp Val Glu Ile  
   1                  5                  10                  15  
 Arg Gly Leu Pro Asn Leu Asn Trp Trp Gln Arg Asp Ala Phe Ile Glu  
                   20                  25                  30  
 Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
           35                  40                  45  
 Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
   50                  55

<210> 28  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

- 12 -

&lt;400&gt; 28

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Asp Ala Trp Val Glu Ile  
 1 5 10 15

Lys Ser Leu Pro Asn Leu Asn Trp Phe Gln Arg Asp Ala Phe Ile Ala  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 29

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 29

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
 1 5 10 15

Lys Arg Leu Pro Asn Leu Asn Trp Tyr Gln Arg Asp Ala Phe Ile Tyr  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 30

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 30

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Thr Ala Trp Val Glu Ile  
 1 5 10 15

Lys Leu Leu Pro Asn Leu Asn Trp Asn Gln Arg Ala Ala Phe Ile Asp  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

- 13 -

<210> 31  
<211> 58  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

<400> 31  
Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Leu Ala Trp Val Glu Ile  
1 5 10 15  
Lys His Leu Pro Asn Leu Asn Trp Trp Gln Arg Asp Ala Phe Ile Arg  
20 25 30  
Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45  
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

<210> 32  
<211> 58  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

<400> 32  
Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
1 5 10 15  
Lys Gln Leu Pro Asn Leu Asn Trp Trp Gln Arg Glu Ala Phe Ile Gly  
20 25 30  
Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
35 40 45  
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
50 55

<210> 33  
<211> 58  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Modified  
bacterial receptor sequence

- 14 -

&lt;400&gt; 33

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Met Ala Trp Val Glu Ile  
 1 5 10 15

Lys Leu Leu Pro Asn Leu Asn Tyr Phe Gln Arg Asp Ala Phe Ile Met  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 34

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 34

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Ala Ala Trp Val Glu Ile  
 1 5 10 15

Lys Arg Leu Pro Asn Leu Asn Trp Met Gln Arg Asp Ala Phe Ile Val  
 20 25 30

Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 35

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 35

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Asp Ala Trp Val Glu Ile  
 1 5 10 15

Lys Thr Leu Pro Asn Leu Asn Trp Tyr Gln Arg Arg Ala Phe Ile Gly  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

- 15 -

<210> 36  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

<400> 36  
 Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Glu Ala Trp Val Glu Ile  
   1                  5                  10                  15  
 Lys Asn Leu Pro Asn Leu Asn Trp Arg Gln Arg Asp Ala Phe Ile Gly  
                   20                  25                  30  
 Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
           35                  40                  45  
 Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
       50                  55

<210> 37  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

<400> 37  
 Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Lys Ala Trp Val Glu Ile  
   1                  5                  10                  15  
 Lys Thr Leu Pro Asn Leu Asn Trp Arg Gln Arg Asp Ala Phe Ile Leu  
                   20                  25                  30  
 Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
       35                  40                  45  
 Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
       50                  55

<210> 38  
 <211> 58  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

- 16 -

&lt;400&gt; 38

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Val Ala Trp Val Glu Ile  
 1 5 10 15

Lys Asn Leu Pro Asn Leu Asn Trp Val Gln Arg Glu Ala Phe Ile Gly  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 39

&lt;211&gt; 58

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 39

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Ala Ala Trp Val Glu Ile  
 1 5 10 15

Lys Arg Leu Pro Asn Leu Asn Trp Met Gln Arg Asp Ala Phe Ile Val  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys  
 50 55

&lt;210&gt; 40

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Modified  
 bacterial receptor sequence

&lt;400&gt; 40

Val Asp Asn Lys Phe Asn Lys Glu Trp Arg Lys Ala Trp Val Glu Ile  
 1 5 10 15

Lys Val Leu Pro Asn Leu Asn Glu Ser Gln Lys Gly Ala Phe Ile Met  
 20 25 30

Ser Leu Leu Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala  
 35 40 45

Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Cys  
 50 55

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/00732

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07K 14/31, C12N 15/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07K, C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9519374 A1 (NILSSON, BJÖRN ET AL), 20 July 1995 (20.07.95), page 4, line 30 - page 10, line 23, figure 14, abstract	1-7,9-10,12, 14,16-23
A	-- -----	8,11,13,15

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

28 July 2000

Date of mailing of the international search report

03-08-2000

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Henrik Nilsson/gh

Telephone No. +46 8 782 25 00



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE 00/00732

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9519374 A1	20/07/95	AU 676022 B	27/02/97
		AU 696186 B	03/09/98
		AU 1548795 A	01/08/95
		AU 6158794 A	14/09/94
		BR 9406373 A	16/01/96
		CA 2181042 A	20/07/95
		EP 0686319 A	13/12/95
		EP 0739353 A	30/10/96
		FI 953953 A	23/08/95
		JP 8506949 T	23/07/96
		JP 9508016 T	19/08/97
		NO 953307 A	19/10/95
		NZ 278991 A	24/04/97
		SE 9400088 D	00/00/00
		US 5831012 A	03/11/98
-----			